Gamma knife is an outpatient procedure that allows the patient to travel back home the same day of treatment. Gamma knife is a highly focused radiation therapy for brain or spinal cancer involving a single treatment high-dose radiation therapy. Cyberknife on the other hand, which can treat cancer anywhere in the body, involves one to five radiation treatment capability. Gamma knife therapy is considered to be much safer than the open-skull surgeries owing to these factors. The global gamma knife market is expected to grow gradually with increase in awareness. There are more than 300 gamma knife centers worldwide at present, which are estimated to treat nearly 60,000 patients every year. However, there still exists a high demand-supply gap in the countries in pacific region, and Africa continent. China, India, Thailand, South Korea, and Japan are leading countries in terms of the number of gamma knife centers. The gamma knife market is therefore considerable in this region, however behind North America and Europe where the number of gamma knife centers exists far more than Asia.

Non-invasive precision therapy to favor the growth of global gamma knife market
Gamma knife radiotherapy involves convergence of 201 beams that can treat the tumor cell leaving precisely leaving the surrounding healthy cells undamaged. Utilizing the pre-operative diagnostic images form CT/MRI scan, the instrument provides highly accurate irradiation at the tumor site. This is a major factor that drives the usage of gamma knife radiotherapy in treating brain tumors. Application of this procedure is increasing further in trigeminal neuralgia, and arteriovenous malformations. However, gamma knife is limited to 190 positions to reach the tumor cells.
Alternative treatment options include Cyberknife, LINAC radiosurgery, conventional brain surgery, proton therapy, and modified linear accelerators. Gamma knife is the most researched and established radiosurgery. There are over 2,500 published studies for gamma knife.

Potential target population for the global gamma knife market
American Brain Tumor Association:
Incidence of metastatic brain tumors is estimated in the range of 200,000-300,000 cases annually

Incidence is high in the age group of 45-64 years
Approximately 80,000 new cases of primary brain tumors is expected in 2017
Around 700,000 people in the U.S. living with a primary brain and CNS tumor as of 2016
American Association of Neurological Surgeons:
Around 150,000 new cases of trigeminal neuralgia are diagnosed annually in the U.S.
Disease is more common in women than men
International Association for the Study of Pain (IASP):
Global prevalence is in the range of 0.01% to 0.3% (2014)
Considering the current number of patients being treated i.e. 60,000, there exists a major growth potential for gamma knife market. Installation of gamma knife equipment at various locations to improve accessibility would propel the gamma knife market growth in near future.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.